Taselisib (GDC-0032) is a newly discovered A β-Sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.

CAS：1282512-48-4
中文别名：GDC-0032;
英文别名：S7103,GDC0032,RG7604;2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide;4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl-1H-pyrazole-1-acetamide;2-{3-[2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide;2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid;
分子式：C24H28N8O2
分子量：460.532
精确质量：460.234
Psa：118.67
Logp：3.8745

密度：1.4±0.1g/cm3
沸点：783.3±70.0°Cat760mmHg
闪点：427.5±35.7°C
外观性状：粉末
蒸汽压：0.0±2.7mmHgat25°C
折射率：1.709
储存条件：-20℃